Warning letter
Darmerica, LLC: warning letter of Dec 8, 2025
FDA warning letter 716152 · Center for Drug Evaluation and Research (CDER)
Key facts
| Reference number | 716152 |
|---|---|
| Company | Darmerica, LLC |
| Subject | CGMP/Active Pharmaceutical Ingredient (API)/Adulterated/Misbranded |
| Issue date | Dec 8, 2025 |
| Posted date | Dec 23, 2025 |
| Issuing office | Center for Drug Evaluation and Research (CDER) |
| Product type | Drugs |
| CFR sections cited | 207.41(a), 201, 207, 207.49(a)(4) |
| Inspection city | Davie |
| Inspection ZIP | 33314-2239 |
| Inspection start date | Mar 3, 2025 |
| Letter on fda.gov | fda.gov |
At a glance
- 1–9 CFR sections cited
- Yes Form FDA 483 issued
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About FDA warning letters
FDA warning letters notify a firm of significant regulatory violations found during an inspection or review and request prompt corrective action.
Source: U.S. Food and Drug Administration (FDA), Warning Letters · Source date: